Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
14.77
-0.18 (-1.20%)
At close: Oct 17, 2025, 4:00 PM EDT
14.80
+0.03 (0.20%)
Pre-market: Oct 20, 2025, 8:32 AM EDT
Xencor Revenue
Xencor had revenue of $43.61M in the quarter ending June 30, 2025, with 82.41% growth. This brings the company's revenue in the last twelve months to $146.93M, down -2.07% year-over-year. In the year 2024, Xencor had annual revenue of $110.49M, down -36.72%.
Revenue (ttm)
$146.93M
Revenue Growth
-2.07%
P/S Ratio
7.17
Revenue / Employee
$587,716
Employees
250
Market Cap
1.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
XNCR News
- 5 days ago - Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 4 weeks ago - Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release - Seeking Alpha
- 7 weeks ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Xencor Reports Second Quarter 2025 Financial Results - Business Wire
- 2 months ago - Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors - Business Wire
- 5 months ago - Xencor Reports First Quarter 2025 Financial Results - Business Wire
- 6 months ago - Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - Business Wire
- 7 months ago - Xencor Appoints Todd Simpson to Board of Directors - Business Wire